Ana Navascués
About
Ana Navascués is a scholar working on Epidemiology, Infectious Diseases and Modeling and Simulation.
According to data from OpenAlex, Ana Navascués has authored 67 papers receiving a total of 911 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Epidemiology, 30 papers in Infectious Diseases and 11 papers in Modeling and Simulation. Recurrent topics in Ana Navascués's work include Respiratory viral infections research (26 papers), Influenza Virus Research Studies (21 papers) and COVID-19 epidemiological studies (11 papers). Ana Navascués is often cited by papers focused on Respiratory viral infections research (26 papers), Influenza Virus Research Studies (21 papers) and COVID-19 epidemiological studies (11 papers). Ana Navascués collaborates with scholars based in Spain, United States and Australia. Ana Navascués's co-authors include Jesús Castilla, Carmen Ezpeleta, Iván Martínez‐Baz, Itziar Casado, Marcela Guevara, Camino Trobajo‐Sanmartín, Aitziber Aguinaga, Cristina Burgui, Ana Miqueleiz and Manuel Garcìa Cenoz and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Scientific Reports.
In The Last Decade
Ana Navascués
63 papers receiving 894 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ana Navascués Spain | 18 | 503 | 438 | 158 | 143 | 87 | 67 | 911 | ||
| Abdirahman Mahamud United States | 17 | 390 0.8× | 363 0.8× | 161 1.0× | 77 0.5× | 166 1.9× | 32 | 834 | ||
| Sharon Balter United States | 14 | 832 1.7× | 440 1.0× | 196 1.2× | 104 0.7× | 38 0.4× | 30 | 1.3k | ||
| Liselotte van Asten Netherlands | 19 | 612 1.2× | 396 0.9× | 55 0.3× | 161 1.1× | 51 0.6× | 48 | 995 | ||
| J. Kevin Yin Australia | 17 | 506 1.0× | 197 0.4× | 149 0.9× | 65 0.5× | 21 0.2× | 35 | 697 | ||
| Sonia Tamames Spain | 18 | 466 0.9× | 164 0.4× | 183 1.2× | 102 0.7× | 45 0.5× | 52 | 700 | ||
| Marc Rondy United States | 14 | 542 1.1× | 219 0.5× | 156 1.0× | 83 0.6× | 24 0.3× | 30 | 748 | ||
| Supamit Chunsuttiwat Thailand | 18 | 505 1.0× | 517 1.2× | 104 0.7× | 78 0.5× | 39 0.4× | 24 | 1.0k | ||
| Daniela Pițigoi Romania | 16 | 569 1.1× | 292 0.7× | 153 1.0× | 104 0.7× | 21 0.2× | 52 | 773 | ||
| Concepción Grajales-Muñíz Mexico | 9 | 411 0.8× | 308 0.7× | 44 0.3× | 136 1.0× | 42 0.5× | 36 | 706 | ||
| Jessica E. Atwell United States | 14 | 508 1.0× | 263 0.6× | 252 1.6× | 55 0.4× | 18 0.2× | 30 | 770 |
Countries citing papers authored by Ana Navascués
Since
Specialization
Citations
This map shows the geographic impact of Ana Navascués's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Navascués with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Navascués more than expected).
Fields of papers citing papers by Ana Navascués
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ana Navascués. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Navascués. The network helps show where Ana Navascués may publish in the future.
Co-authorship network of co-authors of Ana Navascués
This figure shows the co-authorship network connecting the top 25 collaborators of Ana Navascués. A scholar is included among the top collaborators of Ana Navascués based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Navascués. Ana Navascués is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Trobajo‐Sanmartín, Camino, Ana Navascués, Itziar Casado, et al.. (2025). Hospitalisation due to respiratory syncytial virus in a population-based cohort of older adults in Spain, 2016/17 to 2019/20. Eurosurveillance. 30(10).
2.
Martínez‐Baz, Iván, Camino Trobajo‐Sanmartín, Miguel Fernández-Huerta, et al.. (2025). Effectiveness and Impact of Autumn 2023 COVID‐19 Vaccination in Preventing Hospitalizations in Navarre, Spain, October 2023 to September 2024. Influenza and Other Respiratory Viruses. 19(9). e70163–e70163.
3.
Ezpeleta, Guillermo, Ana Navascués, S. Belloc, et al.. (2024). Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study. Vaccines. 12(4). 383–383.
4.
Martínez‐Baz, Iván, Camino Trobajo‐Sanmartín, Ana Miqueleiz, et al.. (2024). Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021–2022. Vaccines. 12(1). 58–58.
5.
Trobajo‐Sanmartín, Camino, Ana Navascués, Miguel Fernández-Huerta, et al.. (2024). Prevalence of Respiratory Viral Infections in Deceased Persons during the COVID-19 Pandemic Season 2021–2022: A Population-Based Observational Study. Viruses. 16(4). 533–533.
6.
Martínez‐Baz, Iván, Ana Navascués, Camino Trobajo‐Sanmartín, et al.. (2024). Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study. International Journal of Infectious Diseases. 151. 107364–107364.
7.
Martínez‐Baz, Iván, Camino Trobajo‐Sanmartín, Ana Miqueleiz, et al.. (2023). Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. Eurosurveillance. 28(5).
8.
Martínez‐Baz, Iván, Miguel Fernández-Huerta, Ana Navascués, et al.. (2023). Influenza Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Cases and Hospitalizations in Navarre, Spain, 2022–2023. Vaccines. 11(9). 1478–1478.
9.
Castilla, Jesús, Ana Miqueleiz, Camino Trobajo‐Sanmartín, et al.. (2022). Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022. Eurosurveillance. 27(33).
10.
Trobajo‐Sanmartín, Camino, Iván Martínez‐Baz, Ana Miqueleiz, et al.. (2022). Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. Microbiology Spectrum. 10(2). e0000822–e0000822.
11.
Martínez‐Baz, Iván, Itziar Casado, Ana Miqueleiz, et al.. (2022). Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22. Eurosurveillance. 27(26).
12.
Trobajo‐Sanmartín, Camino, Ana Miqueleiz, Marcela Guevara, et al.. (2022). Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants. The Journal of Infectious Diseases. 227(3). 332–338.
13.
Martínez‐Baz, Iván, Camino Trobajo‐Sanmartín, Ana Miqueleiz, et al.. (2021). Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Eurosurveillance. 26(39).
14.
Trobajo‐Sanmartín, Camino, et al.. (2021). Self-Collection of Saliva Specimens as a Suitable Alternative to Nasopharyngeal Swabs for the Diagnosis of SARS-CoV-2 by RT-qPCR. Journal of Clinical Medicine. 10(2). 299–299.
15.
Muñoz‐Almagro, Carmen, Cristian Launes, Ana Navascués, et al.. (2021). Surveillance for Enteroviruses Associated with Hand, Foot, and Mouth Disease, and Other Mucocutaneous Symptoms in Spain, 2006–2020. Viruses. 13(5). 781–781.
16.
Castilla, Jesús, Marcela Guevara, Ana Miqueleiz, et al.. (2021). Risk Factors of Infection, Hospitalization and Death from SARS-CoV-2: A Population-Based Cohort Study. Journal of Clinical Medicine. 10(12). 2608–2608.
17.
Martínez‐Baz, Iván, Ana Miqueleiz, Itziar Casado, et al.. (2021). Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Eurosurveillance. 26(21).
18.
Martínez‐Baz, Iván, Camino Trobajo‐Sanmartín, Ana Navascués, et al.. (2020). Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers. Vaccines. 8(4). 611–611.
19.
Aguinaga, A., et al.. (2018). Uncomplicated urinary tract infections. Antimicrobial susceptibility study in Navarre. Anales del Sistema Sanitario de Navarra. 41(1). 17–26.
20.
Mira, José Joaquín, Irene Carrillo, Javier González de Dios, et al.. (2018). Low-value clinical practices and harm caused by non-adherence to ‘do not do’ recommendations in primary care in Spain: a Delphi study. International Journal for Quality in Health Care. 31(7). 519–526.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Abdirahman Mahamud Breakdown of academic impact, for papers by Sharon Balter Breakdown of academic impact, for papers by Liselotte van Asten Breakdown of academic impact, for papers by J. Kevin Yin Breakdown of academic impact, for papers by Sonia Tamames Breakdown of academic impact, for papers by Marc Rondy Breakdown of academic impact, for papers by Supamit Chunsuttiwat Breakdown of academic impact, for papers by Daniela Pițigoi Breakdown of academic impact, for papers by Concepción Grajales-Muñíz Breakdown of academic impact, for papers by Jessica E. Atwell